Key Statistics
Each statistic below includes a citation-ready sentence. Copy and use directly in articles, reports, or presentations.
Verified Deals Analyzed
Ambrosia Ventures has analyzed over 2,600 verified biopharma licensing and M&A transactions from 2020 to 2026. Source: Ambrosia Ventures Deal Intelligence Platform.
Phase 2 Oncology Median Upfront
Phase 2 oncology licensing deals average $95M upfront (median, 2020-2026). Source: Ambrosia Ventures.
Phase 2 Oncology Median Total Deal Value
Phase 2 oncology licensing deals have a median total deal value of $1.1 billion, including upfront, milestones, and royalties (2020-2026). Source: Ambrosia Ventures.
ADC Modality Premium Over Small Molecules
Antibody-drug conjugate (ADC) licensing deals command a 1.50x premium over small molecule baselines across all phases (2020-2026). Source: Ambrosia Ventures.
Immunology vs Oncology Phase 2 Upfront Ratio
Immunology Phase 2 upfront payments ($120M median) now exceed oncology ($95M) by approximately 26%, reflecting a roughly 4:1 immunology-to-oncology upfront ratio when adjusted for deal volume (2024-2026). Source: Ambrosia Ventures.
Phase 2 Metabolic/Obesity Median Upfront
Phase 2 metabolic and obesity licensing deals command the highest median upfront of any therapeutic area at $150M (2020-2026). Source: Ambrosia Ventures.
Therapeutic Areas Covered
Ambrosia Ventures benchmarks cover 12 therapeutic areas including oncology, immunology, neurology, metabolic, cardiovascular, hematology, ophthalmology, infectious disease, rare disease, dermatology, gastroenterology, and women's health. Source: Ambrosia Ventures.
Company Profiles Tracked
The platform tracks over 850 biopharma company profiles with pipeline, deal history, and partnership data updated weekly. Source: Ambrosia Ventures.
Embeddable Charts
Embed interactive charts directly into your publication. Each chart is responsive, auto-updates with new data, and links back to the full dataset.
Phase Upfront Staircase (Oncology)
Median upfront payments across 7 development phases for oncology licensing deals.
Embed Code
<iframe src="https://calculator.ambrosiaventures.co/api/embed/chart?type=phase-upfront&theme=light" width="100%" height="400" style="border:1px solid #e2e8f0;border-radius:12px;" title="Phase Upfront Staircase (Oncology)" loading="lazy"></iframe>Therapeutic Area Comparison (Phase 2 Upfronts)
Side-by-side Phase 2 median upfronts across 12 therapeutic areas.
Embed Code
<iframe src="https://calculator.ambrosiaventures.co/api/embed/chart?type=ta-comparison&theme=light" width="100%" height="400" style="border:1px solid #e2e8f0;border-radius:12px;" title="Therapeutic Area Comparison (Phase 2 Upfronts)" loading="lazy"></iframe>Modality Premiums
Multiplier premiums by modality relative to small molecule baselines.
Embed Code
<iframe src="https://calculator.ambrosiaventures.co/api/embed/chart?type=modality-premiums&theme=light" width="100%" height="400" style="border:1px solid #e2e8f0;border-radius:12px;" title="Modality Premiums" loading="lazy"></iframe>Territory Value Split
Deal value distribution across global, US-only, ex-US, and regional licensing structures.
Embed Code
<iframe src="https://calculator.ambrosiaventures.co/api/embed/chart?type=territory-split&theme=light" width="100%" height="400" style="border:1px solid #e2e8f0;border-radius:12px;" title="Territory Value Split" loading="lazy"></iframe>Methodology
All benchmarks are derived from a proprietary database of 2,600+ verified biopharma licensing and M&A transactions executed between 2020 and 2026. Primary sources include SEC filings (8-K, 10-K, 10-Q), company press releases, investor presentations, and regulatory databases. Every deal record includes upfront payment, milestone structure, royalty terms, development phase, therapeutic area, modality, and territory scope.
Deal values are reported as median figures to minimize distortion from mega-deals. Modality premiums are calculated as multipliers relative to small molecule baselines at matched phases and therapeutic areas. New transactions are ingested weekly via automated SEC EDGAR monitoring and manual verification. For full methodology details, data sourcing criteria, and statistical methods, see the complete methodology page.
Brand Assets
Use these assets when referencing Ambrosia Ventures in publications.
Brand Colors
Teal
#0EA5A5
Navy
#141831
Slate
#64748B
Usage Guidelines
- ✓Use "Ambrosia Ventures" in full
- ✓Link to calculator.ambrosiaventures.co
- ✓Cite source when quoting data
- ✗Do not alter logo colors
Boilerplate Copy
50-Word Version
Ambrosia Ventures provides data-driven deal intelligence for biopharma licensing professionals. The platform analyzes 2,600+ verified transactions across 12 therapeutic areas, offering real-time benchmarks for upfront payments, milestones, and royalties. Used by BD teams, investors, and consultants to benchmark and structure biopharma partnerships.
100-Word Version
Ambrosia Ventures is a life sciences deal intelligence platform that helps biotech founders, BD teams, investors, and consultants benchmark and structure biopharma licensing deals. Drawing from 2,600+ verified transactions across 12 therapeutic areas, the platform provides real-time benchmarks for upfront payments, milestone structures, royalty rates, and total deal values. Features include comparable transaction analysis, risk-adjusted NPV modeling, Monte Carlo simulation, partner matching, and AI-generated negotiation playbooks. The platform tracks 850+ company profiles and ingests new deal data weekly from SEC filings, press releases, and regulatory databases.
Press Contact
For data requests, expert commentary, or partnership inquiries:
press@ambrosiaventures.coWe respond within 4 hours.
Run Your Own Deal Benchmark
Model upfronts, milestones, and royalties for any phase, modality, and therapeutic area — powered by 2,600+ real transactions.
Data updated daily from SEC filings, press releases, and verified sources.